To flare or not to flare: patients' and rheumatologists' perceptions on the on-flare retreatment strategy of rituximab in rheumatoid arthritis.

perception qualitative research retreatment rheumatoid arthritis rituximab

Journal

Therapeutic advances in musculoskeletal disease
ISSN: 1759-720X
Titre abrégé: Ther Adv Musculoskelet Dis
Pays: England
ID NLM: 101517322

Informations de publication

Date de publication:
2024
Historique:
received: 21 10 2023
accepted: 18 01 2024
medline: 1 3 2024
pubmed: 1 3 2024
entrez: 1 3 2024
Statut: epublish

Résumé

Several retreatment strategies exist for rituximab in rheumatoid arthritis (RA). In some countries, reimbursement criteria require a loss of disease control for rituximab retreatment. Understanding the patients' and rheumatologists' perceptions regarding this retreatment strategy would be informative in identifying the optimal treatment administration schedule. This study aimed to uncover patients' and rheumatologists' perceptions regarding retreatment strategies of rituximab. Qualitative study - semi-structured interviews. Patients with RA, treated with rituximab, and rheumatologists were invited to participate in a qualitative study consisting of individual, in-depth, semi-structured interviews. Interviews were analysed according to the Qualitative Analysis Guide of Leuven. A total of 16 patients and 13 rheumatologists were interviewed. Benefits (e.g. decreased risk of overtreatment, cost savings and long-lasting effectiveness of rituximab) and barriers (e.g. fluctuating disease activity, slow mode of action and increased glucocorticoid use) of on-flare retreatment were identified. To effectively treat on-flare, flares must first be identified timely. Both stakeholder groups acknowledged that patients are capable of recognizing flares. However, the patient's ability to discriminate between inflammatory and other types of pain was perceived as difficult. Furthermore, patients and rheumatologists stressed that patients must timely seek professional help in case of a flare, followed by a swift response from the rheumatologists. Remarkably, retreatment was approached in various ways among rheumatologists, and not always adhering strictly to the on-flare reimbursement criteria. This study revealed that both stakeholder groups perceived the heterogeneity in recognition of and reaction to a flare as important in influencing the effectiveness of the on-flare retreatment strategy. Moreover, this study identified the benefits and barriers of treating on-flare, which could be informative for daily practice decisions.

Sections du résumé

Background UNASSIGNED
Several retreatment strategies exist for rituximab in rheumatoid arthritis (RA). In some countries, reimbursement criteria require a loss of disease control for rituximab retreatment. Understanding the patients' and rheumatologists' perceptions regarding this retreatment strategy would be informative in identifying the optimal treatment administration schedule.
Objectives UNASSIGNED
This study aimed to uncover patients' and rheumatologists' perceptions regarding retreatment strategies of rituximab.
Design UNASSIGNED
Qualitative study - semi-structured interviews.
Methods UNASSIGNED
Patients with RA, treated with rituximab, and rheumatologists were invited to participate in a qualitative study consisting of individual, in-depth, semi-structured interviews. Interviews were analysed according to the Qualitative Analysis Guide of Leuven.
Results UNASSIGNED
A total of 16 patients and 13 rheumatologists were interviewed. Benefits (e.g. decreased risk of overtreatment, cost savings and long-lasting effectiveness of rituximab) and barriers (e.g. fluctuating disease activity, slow mode of action and increased glucocorticoid use) of on-flare retreatment were identified. To effectively treat on-flare, flares must first be identified timely. Both stakeholder groups acknowledged that patients are capable of recognizing flares. However, the patient's ability to discriminate between inflammatory and other types of pain was perceived as difficult. Furthermore, patients and rheumatologists stressed that patients must timely seek professional help in case of a flare, followed by a swift response from the rheumatologists. Remarkably, retreatment was approached in various ways among rheumatologists, and not always adhering strictly to the on-flare reimbursement criteria.
Conclusion UNASSIGNED
This study revealed that both stakeholder groups perceived the heterogeneity in recognition of and reaction to a flare as important in influencing the effectiveness of the on-flare retreatment strategy. Moreover, this study identified the benefits and barriers of treating on-flare, which could be informative for daily practice decisions.

Identifiants

pubmed: 38425577
doi: 10.1177/1759720X241232268
pii: 10.1177_1759720X241232268
pmc: PMC10903194
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1759720X241232268

Informations de copyright

© The Author(s), 2024.

Déclaration de conflit d'intérêts

The authors declare that there is no conflict of interest.

Auteurs

Delphine Bertrand (D)

Skeletal Biology and Engineering Research Center, KU Leuven Department of Development and Regeneration, Herestraat 49, Leuven 3000, Belgium.

Anke Deprez (A)

KU Leuven, Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium.
KU Leuven, Department of Public Health and Primary Care, Environment and Health, Leuven, Belgium.

Michaël Doumen (M)

KU Leuven, Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium.
UZ Leuven, Rheumatology, Leuven, Belgium.

Diederik De Cock (D)

KU Leuven, Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium.
Biostatistics and Medical Informatics Research Group, Department of Public Health Sciences, Vrije Universiteit Brussel (VUB), Brussels, Belgium.

Sofia Pazmino (S)

KU Leuven, Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium.
KU Leuven, Department of Chronic Diseases and Metabolism, Clinical and Experimental Endocrinology, Leuven, Belgium.

Anja Marchal (A)

ReumaNet vzw, Zaventem, Belgium.

Marc Thelissen (M)

ReumaNet vzw, Zaventem, Belgium.

Johan Joly (J)

UZ Leuven, Rheumatology, Leuven, Belgium.

Elias De Meyst (E)

KU Leuven, Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium.
UZ Leuven, Rheumatology, Leuven, Belgium.

Barbara Neerinckx (B)

KU Leuven, Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium.
UZ Leuven, Rheumatology, Leuven, Belgium.

René Westhovens (R)

KU Leuven, Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium.
UZ Leuven, Rheumatology, Leuven, Belgium.

Patrick Verschueren (P)

KU Leuven, Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium.
UZ Leuven, Rheumatology, Leuven, Belgium.

Classifications MeSH